[Abtract]Nursing safety management is crucial to patient health outcomes,and real-time monitoring and early warning systems play a vital role in enhancing nursing safety and reducing medical incidents.Wearable flexible devices enable non-invasive,continuous monitoring of various physiological parameters and provide timely alerts.These devices not only improve the efficiency and quality of nursing safety management but also offer patients more convenient,accurate,and personalized care services.This article provides a comprehensive review of the application of wearable flexible devices in nursing safety management,examining their application scenarios,advantages,and challenges,and offering insights to facilitate the further integration of this technology into nursing safety practices.

[Abtract]Nursing safety management is crucial to patient health outcomes,and real-time monitoring and early warning systems play a vital role in enhancing nursing safety and reducing medical incidents.Wearable flexible devices enable non-invasive,continuous monitoring of various physiological parameters and provide timely alerts.These devices not only improve the efficiency and quality of nursing safety management but also offer patients more convenient,accurate,and personalized care services.This article provides a comprehensive review of the application of wearable flexible devices in nursing safety management,examining their application scenarios,advantages,and challenges,and offering insights to facilitate the further integration of this technology into nursing safety practices.

Glioblastoma (GBM) is an exceptionally aggressive tumor that originates in the brain,characterized by a notably high mortality rate and a limited responsiveness to pharmacological interven-tions.In recent years,antibody-drug conjugates (ADCs) have emerged as a focal point in the advance-ment of anti-cancer therapeutic research,merging the precise targeting capabilities of antibodies with the powerful killing power of cytotoxins.In recent years,the outcomes of numerous clinical trials investi-gating ADCs targeted against GBM have been notably encouraging.This article endeavors to provide a comprehensive overview of the prevalent ADCs targets for GBM therapy,which include the epidermal growth factor receptor,the cluster of differentiation,the mannose receptor family,the integrin family,and the galectin family.Furthermore,it will delve into the contemporary landscape of ADCs drug research and the significant challenges encountered in the application of ADCs for GBM treatment.

Glioblastoma (GBM) is an exceptionally aggressive tumor that originates in the brain,characterized by a notably high mortality rate and a limited responsiveness to pharmacological interven-tions.In recent years,antibody-drug conjugates (ADCs) have emerged as a focal point in the advance-ment of anti-cancer therapeutic research,merging the precise targeting capabilities of antibodies with the powerful killing power of cytotoxins.In recent years,the outcomes of numerous clinical trials investi-gating ADCs targeted against GBM have been notably encouraging.This article endeavors to provide a comprehensive overview of the prevalent ADCs targets for GBM therapy,which include the epidermal growth factor receptor,the cluster of differentiation,the mannose receptor family,the integrin family,and the galectin family.Furthermore,it will delve into the contemporary landscape of ADCs drug research and the significant challenges encountered in the application of ADCs for GBM treatment.

Objective:To analyze the effects of two decomposition algorithms of dual-energy cone beam CT (DECBCT) (direct decomposition and iterative decomposition) on the image quality and material decomposition accuracy of different sizes of phantoms.Methods:Different sizes of imaging parts of patients were simulated using the combination of CatPhan604 phantoms and customized annuluses. CBCT with high energy of 140 kVp and low energy of 100 kVp were acquired using the Varian Edge CBCT system. Then the material decomposition of DECBCT images was performed using the two algorithms. The electron density (ED) and contrast-to-noise ratio (CNR) of each material in the CTP682 module were calculated. They were used to assess the decomposition accuracy and image quality of the two algorithms.Results:Based on the values in the Catphan604 manual, both algorithms have high ED accuracy. Only the ED accuracy of four materials of the smallest sized phantom showed statistical difference ( z = -4.21, 4.30, 2.87, 5.45, P < 0.05), but the average relative error was less than 1%. The CNR of the iterative decomposition algorithm was significantly higher than that of the direct decomposition, increasing by 51.8%-703.47%. The increase in the phantom size significantly reduced the accuracy of ED, and the increased amplitude of the relative error was up to a maximum of 2.52%. The large phantom size also reduced the image quality of iterative decomposition, and the decreased amplitude of CNR was up to a maximum of 39.71. Conclusions:Compared with the direct decomposition, the iterative decomposition algorithm can significantly reduce the image noise and improve the contrast without losing the accuracy of electron density in the DECBCT construction of different sizes of phantoms.

Objective:To detect the expression level of RAB39B gene and the effect of RAB39B on autophagy and α-synuclein, and then investigate the role of RAB39B gene mutation c.536dupA in the pathogenesis of Parkinson′s disease.Methods:Based on the novel RAB39B gene c.536 dupamutation identified in the previous work, the recombinant expression plasmid (pcDNA3.1-HA-RAB39B-536) of RAB39B gene with this mutation and wild-type recombinant expression plasmid (pcDNA3.1-HA-RAB39B) of RAB39B gene were constructed, and the recombinant expression plasmid was transfected into N2a cells with liposome as experimental group. The control group was made up with N2a cells transfected with plasmid pcDNA3.1-HA-RAB39B. Real-time polymerase chain reaction, Western blotting, immunofluorescence and immunoprecipitation techniques were used to detect the expression level of mutant RAB39B gene and the effects of RAB39B on autophagy and α-synuclein.Results:In the N2a cell model, the transcription level of mutant RAB39B was about twice that of wild type RAB39B, while the protein level of mutant RAB39B (0.30±0.00) was significantly lower than that of wild type (1.50±0.25, t=8.313, P<0.05). After adding proteasome inhibitor MG132, the protein level of mutant RAB39B increased (0.70±0.10, t=6.925, P<0.05); the level of microtubule-associated protein 1 light chain 3 BⅡ/Ⅰ of mutant RAB39B (3.11±0.30) was significantly lower than that of wild type (7.03±0.20, t=18.831, P<0.05); overexpression of wild type and mutant RAB39B did not affect the level of endogenous α-synuclein; overexpression of wild-type RAB39B resulted in elevated level of exogenous wild-type (p.A53T; from 0.60±0.11 to 1.25±0.08, t=8.254, P<0.05) and mutant (from 0.55±0.08 to 1.15±0.08, t=9.293, P<0.05) α-synuclein. Conclusions:The stability of the RAB39B protein decreased with the appearance of c.536 dupA mutation, the mutant protein may be degraded through the ubiquitin-proteasome pathway, and this mutation may affect the autophagy level of cells. RAB39B protein may interact with α-synuclein in vivo and may be involved in the maintenance of the stable level of α-synuclein.

Objective To investigate the clinical features, treatments and prognoses of pediatric intracranial aneurysms. Methods The clinical and follow-up data of 16 consecutive patients with pediatric intracranial aneurysms (≤16 years), admitted to our hospital from January 2003 to December 2014, were analyzed retrospectively. Results Pediatric intracranial aneurysms in this study accounted for 0.78%of all intracranial aneurysms. Of the 16 children, 14 were male, 2 were female. There were 12 anterior circulation aneurysms and 5 posterior circulation aneurysms; there were 4 large aneurysms (diameter 11-25 mm) and 2 giant aneurysms (diameter≥25 mm);there were 14 complex aneurysms. At a mean follow-up duration of 16.8 months, no death was noted. Of the 12 patients received microsurgical therapy, 10 patients had favorable outcomes (modified Rankin scale [mRS] 0-1) and 2 patients had some sequelae: different degrees of disability (mRS 2-4). Of the 4 patients received endovascular therapy, 3 patients had favorable outcomes (mRS 0-1) and one patient had hemiparesis (mRS 2). Conclusions Pediatric intracranial aneurysms are different from adult intracranial aneurysms. The treatment effects and prognosis are relatively well when we select individualized treatment mode according to the clinical features of pediatric intracranial aneurysms.